Sjogren Maria H
Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC 20307, USA.
J Gastroenterol Hepatol. 2004 Dec;19 Suppl 6:S69-72. doi: 10.1111/j.1440-1746.2004.03635.x.
Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. The basis for effectiveness in these conditions is primarily through modulation of immunological responsiveness, as thymalfasin has been shown to have beneficial effects on numerous immune system parameters and to increase T-cell differentiation and maturation. Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals. In addition, thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.
胸腺法新(胸腺肽α1)是一种免疫调节剂,能够增强Th1免疫反应。它已在多种疾病中评估了其免疫调节活性及相关治疗潜力,包括慢性乙型和丙型肝炎、艾滋病、原发性免疫缺陷病、疫苗接种反应低下及癌症。在这些病症中其有效性的基础主要是通过调节免疫反应性,因为胸腺法新已被证明对众多免疫系统参数有有益作用,并能增加T细胞分化和成熟。当将胸腺组织移植回胸腺切除的动物时,胸腺法新负责免疫功能的重建。此外,胸腺法新已在多种免疫功能障碍的实验模型中显示出疗效,主要是在传染病如肝炎(土拨鼠)和流感(小鼠),以及癌症如黑色素瘤(小鼠)和结直肠癌(大鼠)中,胸腺法新已显示出抗肿瘤作用。